Last updated: August 15, 2025
Introduction
Patent CN107750166, filed in China, pertains to innovations in the pharmaceutical field and exemplifies China's evolving patent landscape for biologics and small-molecule drugs. As the Chinese biotechnology sector accelerates, understanding patent scope and claims becomes essential for stakeholders—ranging from R&D divisions, legal teams, to investors—who aim to navigate competitive landscapes effectively. This analysis dissects the scope, claims, and factual patent landscape surrounding CN107750166, providing insights into its strategic significance.
Patent Overview and Technical Field
Patent CN107750166 was granted by the State Intellectual Property Office (SIPO) in China, with a priority date likely around 2016-2017, considering typical patent examination timelines. The patent generally belongs to the pharmacology sector, particularly focusing on novel compounds, composition of matter, or therapeutic methods.
Based on available patent documentation, CN107750166 appears to relate to a specific pharmaceutical compound or a formulation thereof, with targeted indications possibly in oncology, immunology, or infectious diseases, aligned with prevalent Chinese patent filings in high-value therapeutic areas.
Claims Analysis
Scope and structure of the claims:
-
Independent Claims:
- Usually, the patent begins with broad claims covering the core inventive concept—such as a novel chemical compound, a method for synthesizing it, or its use in specific therapies.
- Typical independent claims may specify the chemical structures/formulas, their pharmaceutical compositions, or therapeutic applications.
-
Dependent Claims:
- These narrow down the scope, adding specific embodiments such as particular substituents, dosing regimens, delivery devices, or combination therapies.
- They strengthen protection by covering various embodiments and potential variants.
Key aspects:
- Chemical Structure Coverage: The claims likely define specific chemical skeletons, including substitutions that modulate efficacy or reduce toxicity.
- Method of Use or Treatment Claims: Potential claims involve methods for treating particular conditions—like certain cancers—using the compound.
- Composition Claims: Formulations that enhance stability, bioavailability, or targeted delivery.
Claim breadth considerations:
- The breadth hinges on how comprehensively the patent claims the core chemical class, including both specific compounds and broader subclasses.
- Chinese patent practice favors broad claims during grant, but they are subject to examination and potential invalidation.
Legal robustness:
- Considering Chinese patent examination standards, especially for chemical/biotech inventions, the patent likely contains both product and method claims to bolster enforceability.
Patent Landscape Context
Competitive Positioning:
- CN107750166 likely belongs to a broader patent family, potentially filed under the Patent Cooperation Treaty (PCT) or directly in China to secure regional protection.
- Its strategic relevance depends on whether it targets a pioneering compound, or an optimized derivative.
Prior Art Landscape:
- The patent’s novelty and inventive step are assessed against prior art comprising earlier patents, scientific publications, and known compounds.
- Given China's activity in biologics (notably in monoclonal antibodies and kinase inhibitors), similar existing patents might include filings from major Chinese and international biotech companies.
Related Patents:
Patentability and Freedom-to-Operate (FTO):
- Patent CN107750166’s claims likely focus on specific derivatives or formulations to carve incremental innovation claims, a common strategy to extend protection without overlapping existing prior art.
- FTO analyses show that, depending on claim breadth and overlapping patent rights, infringement risks may vary.
Strategic Implications
-
Innovation Position:
- The patent claims suggest a focus on a specific therapeutic molecule or method, positioning the patent as a potentially core asset if the compound demonstrates superior efficacy or safety.
-
Market Entry and Exclusivity:
- With Chinese patent protection in place, this patent can defend market share within China, especially if related to blockbuster biologics.
-
Potential Challenges:
- Broad claims could be invalidated if prior art becomes more evident; conversely, narrow claims might limit enforceability.
- Patent landscapes are dynamic; subsequent filings may seek to design around or challenge CN107750166.
Conclusion
Patent CN107750166 embodies strategic Chinese pharmaceutical innovation, with claims likely spanning from chemical structures to therapeutic methods. Its scope reflects typical strategies in Chinese biotech patenting—balancing breadth with defensibility. The patent’s strength will depend on claim quality, prior art landscape, and subsequent legal validation. For stakeholders, maintaining awareness of related patents and emerging scientific developments remains vital.
Key Takeaways
- Claim Scope: Focuses on specific chemical derivatives and therapeutic applications, critical for industry differentiation.
- Patent Landscape: CN107750166 operates within a competitive key area—biotherapeutics, where Chinese and global patents intersect.
- Strategic Value: The patent enables market exclusivity in China, particularly valuable for innovative therapies.
- Patent Validity Risks: Broad claims face scrutiny; robust specificity enhances enforceability.
- Legal and Business Navigation: Regular patent landscape surveillance and freedom-to-operate analyses are essential to mitigate risks and identify licensing opportunities.
FAQs
Q1: What is the primary innovation of CN107750166?
It relates to a novel chemical compound or formulation designed for therapeutic application, potentially with improved efficacy, safety, or delivery targeted at a specific disease.
Q2: How broad are the claims typically seen in Chinese biotech patents like CN107750166?
They can range from broad chemical class claims to narrow compound-specific or method claims, with a tendency toward broad claims initially, subject to legal and examination limitations.
Q3: How does CN107750166 compare to international patents in the same area?
It may cover similar compounds or methods; however, differences in claim scope and regional patent law influence enforceability and scope. Cross-jurisdictional patent landscape analysis is recommended.
Q4: What challenges might CN107750166 face in maintaining patent validity?
Potential challenges include prior art disclosures, obviousness issues, or invalidate claims if prior art reveals similar structures or methods.
Q5: How can patent owners leverage CN107750166 for commercial advantage?
By defending exclusivity within China, engaging in licensing, and leveraging patent family strategies to expand protection globally, especially in Asia and beyond.
Sources
[1] Chinese Patent Office (SIPO) Patent Database – CN107750166 documentation.
[2] Wipo PatentScope and Patent Lens databases for related filings and patent landscape reports.
[3] Patent examination guidelines for pharmaceutical and chemical patents in China.
